Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6378

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6378 01 April 2025 - 15 April 2025

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Stakeholders

Companies sponsors Janssen-Cilag
Others Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
Patient carer groups Black Health Agency for Equality
  Bob Champion Cancer Trust
  Cancer Black Care
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Orchid
  PCaSO - Prostate Cancer Network
  Pelican Cancer Foundation
  Prost8
  Prostate Cancer Research
  Prostate Cancer UK
  Prostate Matters UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tackle Prostate Cancer
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Geriatrics Society
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  Cancer Research UK
  Prostate Cancer Advisory Group
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord (docetaxel, bicalutamide)
  AstraZeneca UK (bicalutamide, goserelin)
  Dr Reddy’s (docetaxel)
  Hospira (docetaxel)
  Ipsen (triptorelin)
  Medac UK (docetaxel)
  Orion Pharma UK (histrelin)
  Sanofi (docetaxel)
  Seacross (docetaxel)
  Sunpharma (bicalutamide)
  Takeda UK (leuprorelin)
  Zentiva (bicalutamide)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  NHS Wales Joint Commissioning Committee
  Scottish Medicines Consortium
  Welsh Government
Relevant research groups Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research
  Pro Cancer Research Fund

Timeline

Key events during the development of the guidance:

Date Update
01 April 2025 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
01 April 2025 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual